Malaria | Novartis

Press Release
Nov 12, 2025

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
Press Release
Nov 23, 2022

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
Press Release
Jun 23, 2022

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Story
Apr 19, 2022

Staying one step ahead of the malaria parasite
Story
Apr 07, 2022

Tackling the health toll of climate change
Press Release
Sep 29, 2021

Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
Press Release
May 18, 2021

Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Story
Aug 06, 2020

Ensuring medicine supply to patients during COVID-19
Press Release
Mar 03, 2020

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
Story
Apr 24, 2019

Asian health experts call for final push to wipe out deadliest form of malaria
Story
Apr 23, 2018

African experts call for renewed global drive to beat malaria
Story
Apr 09, 2018

Meet Martin Grobusch, malaria fighter